1082949-67-4

Basic information

• Product Name: LY2584702
• Synonyms: LY2584702;LY-2584702 (free base);LY2584702 TsOH;4-[4-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-1-methyl-imidazol-2-yl]-1-piperidyl]-1H-pyrazolo[3,4-d]pyrimidine LY2584702;4-[4-[4-[4-Fluoro-3-(trifluoromethyl)phenyl]-1-methyl-1H-imidazol-2-yl]-1-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidine;4-[4-[4-[4-Fluoro-3-(trifluoromethyl)phenyl]-1-methylimidazol-2-yl]piperidin-1-yl]-1H-pyrazolo
• CAS NO: 1082949-67-4
• Molecular Formula: C₂₁H₁₉F₄N₇
• Molecular Weight: 445.43
• EINECS: -0
• Product Categories: Inhibitors
• Mol File: 1082949-67-4.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: RT (des.)
• Solubility: Soluble in DMSO (up to 1 mg/ml) or in DMF (up to 3 mg/ml).
• Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO or DMF may be stored at -20° for up to 3 months.
• CAS DataBase Reference: LY2584702(CAS DataBase Reference)
• NIST Chemistry Reference: LY2584702(1082949-67-4)
• EPA Substance Registry System: LY2584702(1082949-67-4)

Safety Data

• Hazardous Substances Data: 1082949-67-4(Hazardous Substances Data)

Usage

Description

LY2584702, also known as LYS6K2, is a selective inhibitor of the p70 ribosomal S6 kinase (S6K). It is an orally available compound that blocks the phosphorylation of S6 at concentrations as low as 0.1-0.3 μM, with no activity at GSK3β and Erk1/2 at 10 μM. LY2584702 is a useful tool for dissecting insulin receptor signaling pathways and has demonstrated potential antineoplastic activity.

Uses

Used in Anticancer Applications:
LY2584702 is used as an antineoplastic agent for its potential to inhibit p70S6K signaling, which plays a role in cell growth and proliferation. It has shown potential in anti-tumor treatment when used in combination with other drugs such as Erlotinib or Everolimus.
Used in Research:
LY2584702 is used as a research tool to study the role of p70S6K in insulin receptor signaling pathways. It has been employed to demonstrate that the action of mTORC1 on SREBP-1c expression is not mediated by S6K. As a cell-permeable compound, it allows for easier investigation of the effects of p70S6K inhibition on cellular processes.
Used in Drug Development:
In the pharmaceutical industry, LY2584702 is used as a starting point for the development of new drugs targeting p70S6K signaling. Its selectivity and potency make it a valuable compound for designing more effective and targeted therapies for various types of cancer.

References

1) Fenton et al. (2011), Functions and regulation of the 70kDa ribosomal S6 kinases; Int. J. Biochem. Cell Biol., 43 47 2) Li et al. (2010), Bifurcation of insulin signaling pathway in the rat liver: mTORC1 required for stimulation of lipogenesis, but no inhibition of gluconeogenesis; Proc. Natl. Acad. Sci. USA 107 3441

Upstream product

• 1082950-60-4 tert-butyl 4-(4-(4-fluoro-3-(trifluoromethyl)phenyl)-1-methyl-1H-imidazol-2-yl)piperidine-1-carboxylate 
• 5399-92-8 4-chloro-1H-pyrazolo[3,4-d]pyrimidine 

Downstream Products

• 1082948-81-9 4-{4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine hydrochloride 
• 1082949-68-5 4-{4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine p-toluenesulfonate 

Relevant articles and documents

P70 S6 KINASE INHIBITORS

The present invention provides p70 S6 kinase inhibitors of the formula: pharmaceutical formulations comprising them, and methods for their use.